This early-stage study tests a new drug called IBRX-042 in people with HPV-related cancers that have come back or gotten worse. The main goals are to find the safest dose and see what side effects occur. Twelve participants will receive three injections of the drug, one every thr…
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC